Icon (BSP:ICLR34) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:ICLR34 Icon PLC BSP:ICLR34
68 GF Score
Price R$42.48
GF Value R$58.21
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Icon Net Loan?

Net Loan only applies to banks and insurance companies.

BSP:ICLR34
68GF Score
Icon PLC BSP:ICLR34
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Icon (BSP:ICLR34) Overvalued in 2026?

Based on GuruFocus' analysis, Icon stock appears to be undervalued. The current stock price of R$42.48 is trading 27% below its estimated GF Value™ of R$58.21. GuruFocus considers Icon to be Modestly Undervalued.

Key valuation signals for BSP:ICLR34:

  • Net Loan:
  • GF Value™: R$58.21 vs. price of R$42.48 (27% below fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the BSP:ICLR34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Icon Business Description

Other Exchanges ICLR:USAIJF:Germany
Address South County Business Park, Leopardstown, Dublin, IRL, D18 X5R3
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.
68GF Score

Get the complete analysis for BSP:ICLR34

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$42.48
Price
R$58.21
GF Value